Abgenix

Abgenix was a biotechnology company focused on developing targeted antibody therapies for diseases like cancer. They specialized in creating human antibodies that can precisely bind to specific proteins on cancer cells, helping the immune system recognize and attack tumors. Their platform, XenoMouse, used genetically engineered mice to produce fully human antibodies, which could be safer and more effective for patients. Abgenix was known for collaborating with larger pharmaceutical companies to bring these innovative treatments to market. In 2006, Abgenix was acquired by Amgen, a major biotech firm, which integrated their technologies into its own drug development programs.